Bio­haven’s ion chan­nel drug fails piv­otal bipo­lar ma­nia study

Bio­haven’s potas­si­um chan­nel drug has failed a late-stage study in bipo­lar ma­nia, ac­cord­ing to a state­ment in the com­pa­ny’s fourth-quar­ter earn­ings re­port.

The Phase 2 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER